Video
Dr. Hendifar Discusses a 92-Gene Assay of NETs
Author(s):
In Partnership With:
Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).
Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).
This 92-gene assay is a molecular classification of NETs, says Hendifar. The original validation set looked at over 2,000 tumors and sequenced over 22,000 genes to create this reference set of 92 genes.
Hendifar says this assay was done in an effort to better understand and characterize NETs that are diagnosed as an unknown primary.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
